Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
LONITEN vs ALDORIL D30
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Minoxidil is a potassium channel opener that causes direct vasodilation of peripheral arteries. It reduces peripheral vascular resistance and blood pressure by hyperpolarizing vascular smooth muscle cells via activation of ATP-sensitive potassium channels.
Aldoril D30 is a combination of methyldopa, a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow, and hydrochlorothiazide, a thiazide diuretic that inhibits the sodium-chloride symporter in the distal convoluted tubule, decreasing plasma volume and peripheral resistance.
FDA-approved for treatment of hypertension (as a third-line agent in patients who have not responded to other antihypertensives),Off-label: treatment of androgenetic alopecia (topical formulation; oral low-dose minoxidil is also used for hair loss)
Hypertension
10 mg orally twice daily, titrated to 40 mg twice daily for hypertension; for heart failure, start at 2.5-5 mg orally twice daily, max 20 mg twice daily.
Oral: 1 tablet (hydrochlorothiazide 30 mg / methyldopa 500 mg) twice daily; maximum dose: 2 tablets twice daily.
Terminal elimination half-life: 4.2 hours (range 3.5–5.5); clinically, half-life extends to 14–23 hours after chronic dosing due to drug accumulation.
Terminal elimination half-life of hydrochlorothiazide is 6-15 hours; methyldopa half-life is 1.8 hours (normal renal function). In renal impairment, half-life of both components is prolonged.
Primarily metabolized by the liver via glucuronidation (UGT1A1) to inactive metabolites; less than 20% excreted unchanged in urine.
Methyldopa is metabolized by conjugation (catechol-O-methyltransferase) and hepatic sulfation; hydrochlorothiazide is not extensively metabolized and is excreted unchanged by the kidney.
Renal: 85% (12% unchanged, 73% as glucuronide conjugates); biliary/fecal: 3%
Renal: approximately 50% as parent drug and metabolites; biliary/fecal: minimal, less than 5%.
No significant plasma protein binding (<1%); binds to vasular smooth muscle tissue.
Methyldopa: <10% bound to plasma proteins; hydrochlorothiazide: 40-68% bound to albumin.
1.5 L/kg (range 1.2–2.0); large Vd indicates extensive tissue binding, primarily to arteriolar smooth muscle.
Methyldopa: Vd 0.2-0.3 L/kg (distributes into tissues, crosses placenta); hydrochlorothiazide: Vd 0.75-1.5 L/kg (extensively distributed, does not cross blood-brain barrier significantly).
Oral: 95% (rapidly and completely absorbed).
Oral bioavailability of methyldopa is approximately 25% (variable, influenced by gut metabolism); hydrochlorothiazide bioavailability is 65-75%.
No dose adjustment needed for mild to moderate renal impairment (GFR >30 m L/min). For severe renal impairment (GFR <30 m L/min), reduce dose by 50% and monitor closely.
GFR 30-60 m L/min: reduce dose by 50%; GFR <30 m L/min: not recommended.
No specific Child-Pugh based guidelines; use with caution in severe hepatic impairment as drug may accumulate. Reduce initial dose by 50% in Child-Pugh class C.
Child-Pugh Class B or C: contraindicated; use not recommended.
For hypertension: 0.1-0.2 mg/kg orally once daily, titrate to max 0.5 mg/kg/day divided every 12-24 hours, max 50 mg/day.
Not recommended for use in pediatric patients due to lack of safety and efficacy data.
Start at lower end of dosing range (2.5-5 mg twice daily) due to increased sensitivity; titrate slowly. Monitor for orthostatic hypotension and renal function.
Start with lowest dose; monitor for hypotension, electrolyte imbalance, and CNS effects; consider reduced initial dose.
Must be administered under close medical supervision; may cause pericardial effusion, occasionally progressing to cardiac tamponade, especially in patients with renal impairment or those on dialysis.
None
Monitor for pericardial effusion and tamponade; discontinue if effusion occurs and treat appropriately.,May cause severe fluid retention and congestive heart failure; administer with a diuretic.,Can exacerbate angina; use with caution in patients with coronary artery disease.,Hypertrichosis (excessive hair growth) is common; reversible upon discontinuation.,Monitor blood pressure closely; avoid abrupt withdrawal to prevent rebound hypertension.
May cause hemolytic anemia, liver disorders, positive Coombs test, sedation, depression, and hypersensitivity reactions. Hydrochlorothiazide may cause electrolyte imbalance, hyperuricemia, photosensitivity, and exacerbation of systemic lupus erythematosus. Use with caution in renal impairment, hepatic disease, and in patients with a history of drug-induced hemolytic anemia.
Hypersensitivity to minoxidil or any component of the formulation.,Pheochromocytoma (due to risk of catecholamine release).
Active hepatic disease, history of previous methyldopa therapy-associated liver disorders; anuria; hypersensitivity to methyldopa, hydrochlorothiazide, or sulfonamide-derived drugs.
Avoid high-sodium foods and excessive alcohol intake, which can exacerbate fluid retention and hypertension. No specific food interactions with minoxidil itself, but maintain a balanced diet as part of hypertension management.
Food may decrease absorption of methyldopa. Avoid excessive intake of high-potassium foods (e.g., bananas, oranges) unless directed. Hydrochlorothiazide may cause potassium depletion; maintain adequate dietary potassium. Avoid natural licorice as it can worsen hypokalemia.
Pregnancy Category C. Fetal risks: First trimester - limited human data; animal studies show fetal resorptions and cardiovascular anomalies at high doses. Second/third trimesters - possible fetal hypotension, oligohydramnios, and hypertrichosis. Use only if benefit outweighs risk.
First trimester: Limited data; no clear evidence of major malformations but methyldopa crosses placenta. Second and third trimesters: Associated with reduced placental perfusion; possible fetal bradycardia and neonatal hypotension. Hydrochlorothiazide may cause fetal/neonatal jaundice, thrombocytopenia, and electrolyte disturbances.
Excreted in breast milk; M/P ratio unknown. Avoid use while breastfeeding due to potential adverse effects (e.g., hypotension) in the infant.
Methyldopa is excreted in breast milk in low concentrations; M/P ratio approximately 0.2. Hydrochlorothiazide is excreted in minimal amounts; may suppress lactation. Consider risks versus benefits.
No specific dose adjustment recommended; pharmacokinetic changes in pregnancy may require titration based on maternal response and tolerability.
Methyldopa: Pregnancy-induced plasma volume expansion may require dose titration; monitor blood pressure and adjust accordingly. Hydrochlorothiazide: Often avoided in pregnancy due to volume depletion risks; if used, monitor electrolytes and renal function, no pharmacokinetic data necessitate routine dose adjustment.
Initiate at low doses (2.5 mg BID) and titrate slowly to avoid severe hypotension. Monitor for pericardial effusion, especially in patients with renal impairment. Use with a diuretic and beta-blocker to prevent reflex tachycardia and fluid retention. Abrupt discontinuation can cause rebound hypertension.
ALDORIL D30 combines methyldopa (central alpha-2 agonist) and hydrochlorothiazide (thiazide diuretic). Monitor for orthostatic hypotension, especially at initiation. Taper not needed for methyldopa but discontinue if fever or liver dysfunction occurs. Interferes with urinary catecholamine measurements (false elevation). Hydrochlorothiazide may cause hyponatremia, hypokalemia, and hyperglycemia; check electrolytes and glucose periodically.
Take exactly as prescribed; do not stop suddenly without consulting your doctor.,You may experience dizziness or lightheadedness, especially when standing up; rise slowly.,Report unusual weight gain, swelling in ankles or legs, shortness of breath, or chest pain.,You may notice increased hair growth on face, arms, or back; this is reversible after stopping.,Avoid alcohol and excessive salt intake to help control blood pressure.,Use sunscreen and protective clothing as you may become more sensitive to sunlight.,Do not take over-the-counter medications without checking with your doctor.
Take exactly as prescribed, preferably with food to reduce stomach upset.,Rise slowly from sitting or lying down to prevent dizziness.,This drug may make you drowsy; avoid driving or operating machinery until you know how it affects you.,Report fever, unexplained fatigue, jaundice, or dark urine immediately.,Weigh yourself daily and report rapid weight gain or swelling.,Limit alcohol intake as it can increase side effects.,Do not use salt substitutes containing potassium without consulting your doctor.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about LONITEN vs ALDORIL D30, answered by our medical review team.
LONITEN is a Antihypertensive that works by Minoxidil is a potassium channel opener that causes direct vasodilation of peripheral arteries. It reduces peripheral vascular resistance and blood pressure by hyperpolarizing vascular smooth muscle cells via activation of ATP-sensitive potassium channels.. ALDORIL D30 is a Antihypertensive Combination that works by Aldoril D30 is a combination of methyldopa, a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow, and hydrochlorothiazide, a thiazide diuretic that inhibits the sodium-chloride symporter in the distal convoluted tubule, decreasing plasma volume and peripheral resistance.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between LONITEN and ALDORIL D30 depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of LONITEN is: 10 mg orally twice daily, titrated to 40 mg twice daily for hypertension; for heart failure, start at 2.5-5 mg orally twice daily, max 20 mg twice daily.. The standard adult dose of ALDORIL D30 is: Oral: 1 tablet (hydrochlorothiazide 30 mg / methyldopa 500 mg) twice daily; maximum dose: 2 tablets twice daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between LONITEN and ALDORIL D30 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. LONITEN is classified as Category C. Pregnancy Category C. Fetal risks: First trimester - limited human data; animal studies show fetal resorptions and cardiovascular anomalies at high doses. Second/third trimesters -. ALDORIL D30 is classified as Category C. First trimester: Limited data; no clear evidence of major malformations but methyldopa crosses placenta. Second and third trimesters: Associated with reduced placental perfusion; p. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.